AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06143813 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Selective nerve root block (SNRB)
Description: CT/Fluoroscopy guided nerve root block
Study NCT05964179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time extended feeding
Description: Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 14 hours per day.
Study NCT05964179 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: time restricted feeding
Description: Total feeding time (from the first meal or snack to the last meal or snack) is assigned as 8 hours per day.
Study NCT06589713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enpatoran
Description: Participants will receive a single oral dose of enpataron tablets once daily.
Study NCT06669455 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized and combined lifestyle approach
Description: In the SENSS approach five different and complementary lifestyle domains (self-management, exercise, nutrition, sleep and stress) are combined. The process will be guided by a lifestyle coach. The intervention is personalised for each participant. The personal goals are decided based on 'shared decision making' together with the lifestyle coach after using a Parkinson lifestyle decision aid. The level of guidance needed throughout the intervention is based on a 'stepped care approach'.
Study NCT06452732 — intervention group
Intervention type: OTHER
Intervention: MFC for the determination of leukemia stem cell
Description: MFC for the determination of leukemia stem cell
Study NCT06674473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: With robot assistance
Description: Use a portable isokinetic device
Study NCT06674473 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional bodyweight rehabilitation
Description: Use traditional bodyweight rehabilitation
Study NCT05883202 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Connect®
Description: Restoration of multiple implants with a Connect® abutment between the implant and the prosthesis.
Study NCT05883202 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-unit
Description: Restoration of multiple implants with a conventional multi-unit abutment between the implant and the prosthesis.
Study NCT05859139 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DA Scaling Strategies
Description: For this study the intervention will consist of different DA scaling strategies : 1) dissemination of an online DA; 2) dissemination of a paper-based DA; 3) online training for healthcare professionals.
Study NCT06690775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-1-23
Description: 2.4mg/kg intravenous infusion on Day 1 of every 3-week cycle.
Study NCT06690775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-1-23
Description: 3.0 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
Study NCT06690775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-1-23
Description: 3.4 mg/kg intravenous infusion on Day 1 of every 3-week cycle.
Study NCT06690775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim (drug)
Description: 6 mg subcutaneous injection on Day 4 of each cycle.
Study NCT06717035 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EYE001
Description: Defocus incorporated multiple segments (DIMS) clear vs DIMS photochromic
Study NCT06704100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosamprenavir Calcium & Sodium Alginate
Description: 1400 mg FOS-SA BID: 15 ml oral solution containing 1400 mg fosamprenavir calcium and 24.5 mg sodium alginate administered BID
Study NCT06704100 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 ml oral solution containing 1,399 mg microcrystalline cellulose and 24.5 mg sodium alginate
Study NCT06715566 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ActForStroke
Description: ActForStroke is a combination of 10 sessions high-intensity gait training and subsequent with up 7 coaching sessions until 1 year after stroke.
Study NCT06715566 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Usual rehabilitation services
Study NCT06716853 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Temferon
Description: Autologous CD34+-enriched hematopoietic progenitor cells exposed in vitro to specific lentiviral vector encoding for the human interferon-alpha 2 gene. Its expression is tightly controlled by the human TIE2 enhancer/promoter sequence and by a post-transcriptional regulation layer represented by target miRNA sequences. This enables suppression of interferon-alpha2 expression in HSPCs, thereby further increasing the specificity of the delivery strategy for their Tie2 expressing myeloid cell progeny.
Study NCT06716853 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 400mg IV every 6 weeks commencing at D+30
Study NCT06716853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: 40mg QD once PD occurs as assessed at D+30 or at subsequent visits
Study NCT06718062 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aliskiren
Description: Participants in this group will receive Aliskiren (240 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Shenzhen Xinlitai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20138002. The primary objective is to evaluate the non-inferiority of Aliskiren in lowering serum uric acid levels, and its effects on blood pressure and kidney function.
Study NCT06718062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: Participants in this group will receive Losartan (100 mg daily) for the treatment of hypertension combined with hyperuricemia. The medication will be administered orally once a day for 3 months. The drug will be provided by Zhejiang Huahai Pharmaceutical Co., Ltd., with the National Drug Approval No. H20143030. The goal is to compare the efficacy of Losartan in reducing serum uric acid levels with Aliskiren and evaluate its impact on blood pressure and kidney function.
Study NCT06717529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (hyaluronic acid)
Description: The patient will receive one 3mL Sodium Hyaluronate injection containing 75 mg of active substance in one knee joint.
Study NCT06717529 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone Acetate Injection
Description: The patient will receive 2mL of methylprednisolone acetate solution containing 80 mg of the medicine in other knee joint.
Study NCT06714760 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction following parcellar resections of the mandibular gingival region
Description: In our surgical approach, we have used periosteum, galea, or pericranium flaps for reconstruction of bone and tissue defects in the cervicofacial region, with excellent results. To treat mandibular osteoradionecrosis, we harvested periosteum flaps from the radius, demonstrating efficacy in bone regeneration. For minor defects, such as those of the nose, we used flaps from the medial femoral condyle, despite the complexity of harvesting.~The cranial region, particularly the temporo-parietal area, offered excellent vascularization, allowing the use of revascularized flaps for reconstruction of the oral mucosa after removal of carcinomas. These flaps have also been effective in the treatment of pharyngeal fistulas, proving to be a functionally reliable solution for oral cavity and cervicofacial defects.
Study NCT06718257 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine combined with cisplatin or oxaliplatin
Description: Gemcitabine (1000 mg/m², day 1 and 8) and cisplatin (75 mg/m², day 1) or oxaliplatin (85 mg/m², day 1)
Study NCT06718257 — intervention group
Intervention type: DRUG
Intervention: Gemcitabine combined with cisplatin or oxaliplatin, PD-1/L1 and TKI inhibitors
Description: Gemcitabine (1000 mg/m², day 1 and 8), cisplatin (75 mg/m²; day 1) or oxaliplatin (85 mg/m²; day 1), PD-1/L1 agents (200 mg; day 1), and TKI inhibitors (8 mg; per day)
Study NCT06715059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-rehabilitation exercise program
Description: A progressive core stability exercise program will be performed based on motor control principles via an online platform.
Study NCT06715059 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Description: A core stability exercise program will be performed at home.
Study NCT06716268 — intervention group
Intervention type: OTHER
Intervention: phonation and respiratory tasks
Description: Participants performed various tasks to evaluate pelvic floor muscle activity and displacement. These included a maximum voluntary contraction (cutting off the flow of urine mid-stream), a pelvic floor strain (bearing down for a bowel movement), and the Valsalva maneuver to clear the Eustachian tubes. Additionally, phonation and respiratory exercises were conducted, such as producing the ah sound at different pitches, open-mouth exhalation, coughing, and semi-occluded vocal tract (SOVT) exercises using a small coffee straw, commonly used in singing warm-ups to enhance vocal efficiency. Each task lasted 3 seconds, with 1-minute rest intervals to assess their impact on pelvic floor displacement
Study NCT06715410 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CO2
Description: To collect CO2 data
Study NCT06717308 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfort Release® NPWT drape
Description: Comfort Release® NPWT drape- painless and trauma-free removal, as compared to the control NPWT drape.
Study NCT06717945 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam besylate
Description: Patients received an initial dose of remimazolam (0.3mg/kg) for induction and a continuous infusion rate of 1 mg/kg/h for anesthesia maintenance. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
Study NCT06717945 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Patients received an initial dose of propofol (1.0 mg/kg) and a continuous infusion rate of 1-1.5 mg/kg/h. Sedative was adjusted to maintain a bispectral index (BIS) at 40-60 after induction.
Study NCT06717087 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture+lifestyle intervention
Description: 8 weeks Acupuncture treatment for 2-3 times/week, 30min each time and lifestyle intervention((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
Study NCT06717087 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin+lifestyle intervention
Description: 8 weeks Metformin 500 mg three times a day with meals and lifestyle intervention ((1) Daily intake of 1200\~1500kcal of energy, dietary carbohydrate function ratio of 45-55%, lipid energy supply ratio of 20-30%, protein energy ratio of 20-30% (2) At least 150 minutes of moderate-intensity physical activity (e.g., brisk walking) per week (3) Quit smoking and drinking, and adjust psychologically)
Study NCT05608148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: Intravenous injection of GAIA-102 alone
Study NCT05608148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: Intravenous injection of GAIA-102 with dinutuximab, filgrastim, teceleukin combination
Study NCT05608148 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological
Description: Intravenous injection of GAIA-102 with nivolumab combination
Study NCT05202223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Harmony at HOME (H@H)
Description: H@H is a 6-week telehealth intervention delivered by an occupational therapist during weekly visits.
Study NCT05360823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Birth ball
Description: Exercises for childbirth
Study NCT05360823 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Squatting
Description: Exercises for childbirth
Study NCT04826237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Oral dose to be taken with methylprednisolone
Study NCT04826237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: oral dose, standard of care
Study NCT04826237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: oral dose, standard of care
Study NCT04826237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: Drug for intratympanic administration
Study NCT04826237 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Drug for intratympanic administration
Study NCT04826237 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule the same as for statins but without statin
Study NCT04691388 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab combined with anlotinib
Description: All patients will receive sintilimab combined with anlotinib every 3 weeks
Study NCT06022094 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 months of reduced carb menus
Description: Participants will eat a reduced carb menu for 2 months
Study NCT05367869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Impact of Intraoperative Spraying Methylene Blue In Thyroidectomy
Description: General anaesthesia ,supine position with hyperextension to the neck Low collar incision to the neck , incision to the skin and platysma muscle and fascia ,upper and lower flaps are developed ,separation of strap muscles and identification of the thyroid gland after freeing of investing fascia Ligation of the middle thyroid vein and ligation and separation of the superior pedicle away from the external laryngeal nerve At this point of operation and before ligation of inferior pedicle methylene blue 0.05% spraying is applied to the field the amount varies according to size of the thyroid lobe and variation in population and neck size Thyroid gland stained by bluish color , recurrent laryngeal nerve not stained or minimally stained so we can avoid injury to it parathyroid glands get red of the stain after about 3 minutes so we can avoid injury to it thyroid gland lose its stain in about 15 minutes so we can remove any residual and decrease residual tissue or recurrence
Study NCT06005480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepivacaine
Description: Injection of 1.5% Mepivacaine in nerve block
Study NCT06210607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10511 Tablets
Description: HS-10511 tablets for 5\~6 SAD cohorts and 4 MAD cohorts
Study NCT06210607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10511 Tablets Placebo
Description: HS-10511 tablets placebo for 5\~6 SAD cohorts and 4 MAD cohorts
Study NCT06262516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nephroureterectomy
Description: Participants will undergo standard-of-care nephroureterectomy for UTUC.
Study NCT06262516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Nephroureterectomy
Description: Participants will undergo standard-of-care nephroureterectomy for UTUC.
Study NCT06262516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Dissection
Description: Participants will receive lymph node dissection alongside nephroureterectomy for UTUC.
Study NCT05412992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMTS Patch
Description: DMTS applied before surgery and worn for 96 hours
Study NCT05412992 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Matching patches that have no active drug applied before surgery and worn for 96 hours
Study NCT05390164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: skin biopsy
Description: skin biopsy to be analyzed by ELISA
Study NCT04895371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-physiotherapy group
Description: Allocated participants to this group will receive 18 physiotherapy sessions (three sessions per week) during six weeks. in these sessions, physiotherapist will prescribe aerobic, resistive, breathing and functional exercises and airway clearance techniques (if needed) based on result of assessment of patients at the discharge phase. the physiotherapist will use some educational contents for the patient and call him/her to guide the patient about how exercises should be performed (determining frequency, time, intensity and type of exercise). the patient should do exercises until next session and provide a feedback. The patient will be assessed weekly using a pre-designed questionnaire remotely. the progression of interventions will be based on the results of weekly assessment.
Study NCT04895371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Allocated participants to control group will receive one consultation session by the physiotherapist. At this session, patients will be educated about how to perform their daily activities, breathing exercises, walking, using oxygen cylinder and dietary.
Study NCT05575284 — intervention group
Intervention type: PROCEDURE
Intervention: Robot-assisted urological surgery
Description: Patient with programmed robot-assisted urological surgery
Study NCT05747755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADEPT Program
Description: Integration of surveillance for diagnostic errors into usual care, benchmarking and sharing of results across hospitals, expert mentoring of quality and safety personnel in change management, pilot testing and refinement of Safety I and Safety II interventions to reduce systemic causes of diagnostic errors and to increase resilience, thus promoting diagnostic excellence.
Study NCT05253365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Memory Support System
Description: The MSS is a two-page-per-day, pocket-sized calendar/note-taking system with three sections: (a) events; (b) to do's; and (c) journaling for logging important things to be remembered (e.g., news about family/friends). MSS training consists of ten 1-hour sessions delivered over two or six weeks, starting 7-10 days after baseline assessment.
Study NCT06285630 — intervention group
Intervention type: OTHER
Intervention: Observational, no intervation will be made
Description: No intervention will be made, only longitudinal sample collection.
Study NCT05384717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fidget Device
Description: Fidget spinner, stress ball, pop-it, or fidget cube
Study NCT05384717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No intervention
Study NCT04489758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis
Description: Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
Study NCT04489758 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: X-ray velocimetry analyzed by 4Dx XV Ventilation Analysis
Description: Fluoroscopy will be performed for a complete tidal breath and full exhalation at 5 angles (AP, +/- 36 degrees from AP, and +/- 72 degrees from AP) while the patient's arms are raised overhead. 4Dx XV Ventilation Analysis software will be used to analyze these images. Both groups will also undergo pulmonary function testing and take a questionnaire regarding respiratory symptoms.
Study NCT06223217 — intervention group
Intervention type: OTHER
Intervention: Surveys and Questionnaires
Description: The intervention consists of completing the Chinese version of Vascu-QoL scale and the modified version of Vascu-QoL scale
Study NCT05966350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of sensitive neuronopathy - phase 1
Description: Search of positivity with anti-AGO antibodies test
Study NCT05966350 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of sensitive neuronopathy - phase 2
Description: Title of anti-AGO antibodies
Study NCT05966350 — intervention group
Intervention type: OTHER
Intervention: Comparison with Chi2 method
Description: Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a Chi2 method for qualitative data.
Study NCT05966350 — intervention group
Intervention type: OTHER
Intervention: Comparison of data with parametric Test (T-test)
Description: Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography, evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a parametric test (T-test).
Study NCT05966350 — intervention group
Intervention type: OTHER
Intervention: Comparison of data with non-parametric test (ANNOVA)
Description: Clinical data from positive Argonaute (AGO) patients (age, sex, type of neuropathy, clinical manifestations of neuropathy, electroneuromyography , evolution of neuropathy, presence of associated autoimmune disease, response to possible immunomodulatory treatment) will be compared with those of negative patients using a non-parametric (ANNOVA).